Cytokeratin 18 Antibody (SP69) Summary
| Immunogen |
A synthetic peptide corresponding to C-terminus of human Keratin 18.
|
| Marker |
Epithelial Marker
|
| Isotype |
IgG
|
| Clonality |
Monoclonal
|
| Host |
Rabbit
|
| Gene |
KRT18
|
| Purity |
Protein A or G purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Application Notes |
This product is useful for Immunohistochemistry Paraffin. Antigen retrieval can be performed using a Citrate process.
|
Reactivity Notes
Human
Packaging, Storage & Formulations
| Storage |
Store at 4C. Do not freeze.
|
| Buffer |
7.0 ml prediluted antibody with 10mM PBS (pH 7.4) and 1.0% BSA
|
| Preservative |
0.1% Sodium Azide
|
| Purity |
Protein A or G purified
|
Notes
For a positive control use Breast carcinoma.
Alternate Names for Cytokeratin 18 Antibody (SP69)
- Cell proliferation-inducing gene 46 protein
- cell proliferation-inducing protein 46
- CK-18
- CYK18
- Cytokeratin 18
- cytokeratin-18
- K18
- Keratin 18
- keratin, type I cytoskeletal 18
- keratin-18
- KRT18
Background
Cytokeratin 18 (CK-18), a normal constituent of the hepatocyte cytoskeleton) is a standard tumor marker. CK-18 is elevated in patients with non-malignant liver diseases, particularly in those with prominent cytolysis (1). CK-18 and the homologous mouse Endo B are type I IF protein subunits whose expression is restricted in adults to a variety of simple epithelial tissues. Keratin 8 and 18 (CK8/18) are the major keratin pair in simple-type epithelia, as found in the liver, pancreas, and intestine. Transgenic mice that express mutant keratin 18 develop chronic hepatitis, and have an increased susceptibility to drug-induced hepatotoxicity (2). Studies shows that high CK18 expression in tumor cells is associated with reduced invasiveness in vitro and lack of tumorigenicity in nude mice. It has been shown that high K18 expression correlated with a good prognosis and that reducing K18 expression increased the aggressiveness of established breast cancer cell lines (3).